Rhythm Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 65 to 92 Tuesday.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an 80 or better RS Rating as they launch their biggest price moves.
Here Are 3 Keys For Successful Stock Investing
Is Rhythm Pharmaceuticals Stock A Buy?
The IBD 50 stock recently reclaimed its 50- and 200-day moving averages and is trying to complete a consolidation with a 68.58 buy point. The biotech stock belongs on your watchlist. This is not the time to buy stocks during a bear market, but build a watchlist of possible emerging leaders once the market trend turns around.
The relative strength has entered new high ground, a sign the stock is outperforming the general market in terms of price performance.
The biotech firm posted 0% EPS growth in its most recent report. Revenue rose 73%. The company is expected to report its latest performance numbers on or around May 6.
Rhythm Pharmaceuticals stock earns the No. 45 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
